SELLAS reports $138.3 million in cash for its second quarter 2026 and loses its arbitration case against 3D Medicines.

SELLAS Life Sciences Group provided a preliminary update on its cash position as of June 30, 2026, and announced the result of its arbitration proceeding against 3D Medicines. The company reported an unaudited cash balance of $138.3 million.

Key Highlights

• Reported a preliminary, unaudited cash and cash equivalents balance of $138.3 million as of June 30, 2026.
• Lost its binding arbitration case against 3D Medicines, with the arbitrator dismissing the company's claims.
• Ordered to pay approximately $1.0 million of 3D Medicines' legal fees, while $191.5 million in potential future milestone payments from the partnership remain.